Rankings
▼
Calendar
TKNO Q4 2024 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena
TKNO
Alpha Teknova, Inc.
$133M
Q4 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$9M
+17.8% YoY
Gross Profit
$2M
23.0% margin
Operating Income
-$6M
-60.7% margin
Net Income
-$6M
-61.7% margin
EPS (Diluted)
$-0.11
QoQ Revenue Growth
-3.2%
Cash Flow
Operating Cash Flow
-$936,000
Free Cash Flow
-$2M
Stock-Based Comp.
$766,000
Balance Sheet
Total Assets
$119M
Total Liabilities
$36M
Stockholders' Equity
$82M
Cash & Equivalents
$4M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$9M
$8M
+17.8%
Gross Profit
$2M
$1M
+59.4%
Operating Income
-$6M
-$11M
+48.2%
Net Income
-$6M
-$11M
+46.3%
Revenue Segments
Lab Essentials
$7M
74%
Clinical Solutions
$2M
20%
Other Product
$597,000
6%
Geographic Segments
UNITED STATES
$9M
95%
Non-US
$501,000
5%
← FY 2024
All Quarters
Q1 2025 →